Oxford Biomedica Announces Share Transaction by Associated Person

Oxford BioMedica ( (GB:OXB) ) has shared an update.

Oxford Biomedica announced that Pippa Radcliffe, closely associated with the company’s Chief Innovation Officer, Dr. Kyriacos Mitrophanous, exercised 1,209 options and sold 1,209 shares at £2.9785 per share. This transaction, compliant with EU Market Abuse Regulation, reflects internal financial activities and may impact stakeholders’ perceptions of the company’s governance and financial health.

More about Oxford BioMedica

Oxford Biomedica (OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. With 30 years of experience, the company is a pioneer in viral vector development, collaborating with leading pharmaceutical and biotechnology firms. OXB offers expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vectors, with capabilities ranging from early-stage development to commercialization. Headquartered in Oxford, UK, it operates facilities in the UK, France, and the US.

YTD Price Performance: -21.40%

Average Trading Volume: 19,149

Technical Sentiment Signal: Buy

Current Market Cap: $432.5M

Find detailed analytics on OXB stock on TipRanks’ Stock Analysis page.